Bolt Biotherapeutics, Inc. revenue for the last year amounted to 7.88 M USD, the most of which — 7.88 M USD — came from its highest performing source at the moment, Novel Immunotherapies, the year earlier bringing 5.73 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Bolt Biotherapeutics, Inc. 7.88 M USD, and the year before that — 5.73 M USD.